Company intelligence / Profile preview

Endo-Serv

Rochester, Michigan, United Statesendo.com ↗

Ownership: Private
Employees: ~3000
Development stage: Other

Overview

Endo offers marketed therapies in urology, orthopedics, endocrinology, pain, and generics, with key products including XIAFLEX and a large generics portfolio. The company is active in both branded specialty and high-value generic drugs, with several new product lines in sterile injectables and generics launched in 2024 and 2025.

Therapeutic areas: Men's HealthNeurologyEndocrinologyRheumatology
Modalities: Small moleculeBiologicSterile injectableDevice
Industry: Biotech

Drug pipeline

2 assets

XIAFLEX

Commercial

Indications: Peyronie's disease

1 more asset in the full pipeline.

Request access →

Partnerships

American Urological AssociationSexual Medicine Society of North AmericaAmerican Society for Surgery of the Hand

Beyond the preview

Go deeper on Endo-Serv.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Endo-Serv.

Explore the full profile